This month on Nursing Excellence in Cancer Care we discuss living with metastatic ovarian cancer. Available exclusively to members, we encourage you to login and listen today!
Following the 1 March 2026 Pharmaceutical Benefits System (PBS) updated listings for ipilimumab and nivolumab for the treatment of immunotherapy sensitive, advanced or metastatic cancers, eviQ has published its first broad indication tumour-agnostic immunotherapy protocol.
Australia now has clarity it has never had before: 20,950 Australians are living with metastatic breast cancer — more than double what was previously understood. This new national estimate exposes decades of undercounting, underestimated need, and under-resourced care.
From 1 October 2026, Triptorelin 3.75mg (Diphereline®) will become available on the PBS for the treatment of a range of women’s health conditions, including breast cancer, endometriosis and uterine fibrosis.
This practical session focused on supporting people with treatable, but not curable cancers, and included presentations from experts in the field, a consumer with lived experience, and a facilitated panel discussion.
